Hormonal Contraceptive Use and the Risk of Provoked Vestibulodynia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01741948|
Recruitment Status : Withdrawn (the study has never started. my grant request was denied.)
First Posted : December 5, 2012
Last Update Posted : February 10, 2015
|Condition or disease||Intervention/treatment|
|Vestibulodynia||Drug: Hormonal contraceptive|
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Hormonal Contraceptive Use and the Risk of Provoked Vestibulodynia- A Prospective Study|
|Study Start Date :||January 2012|
|Actual Primary Completion Date :||December 2013|
|Actual Study Completion Date :||December 2013|
|First time users of hormonal contraceptive||
Drug: Hormonal contraceptive
The study will follow patients who are first time users of HCs for a full year after initiation. Patients will be followed every 3 months via questionnaires, blood examinations, and gynecologic examination, in case dyspareunia evolves.
First appointment (before initiation of HCs):
Questionnaire FSFI (Female Sexual Function Index) questionnaire. Blood collection for hormones levels and extraction of mononuclear blood cells. A gynecologic exam intended to rule out existing problem which causing dyspareunia.
3,6,9,and 12 months after initiation of HCs or anytime if a patient has dyspareunia:
Questionnaire evaluating possible influence of HCs use (dyspareunia, lubrication and libido).
FSFI questionnaire. Blood collection Gynecologic examination, designated to assess the cause of pain, including assessment of vestibular tenderness, muscle tightness and tenderness, pressure-pain thresholds measurement using vulvar algesiometer, pH measurement and vaginal swab for microscopy.
- Prevalence of hormonal-contraceptive induced provoked vestibulodynia [ Time Frame: One year ]one year for patients' enrollment and another year for follow up.
- Hormonal contraceptive components associated with higher risk of HCs induced PVD [ Time Frame: One year ]Dose of ethinyl estradiol (15, 20 and 30 mcg) The progesterone component
- Clinical factors associated with HCs induced PVD [ Time Frame: One year ]Age at menarche Length of use Body mass index
- Biochemical markers associated with higher risk of HCs induced PVD [ Time Frame: One year ]Hormones: E2, testosterone Altered gene expression
Biospecimen Retention: Samples Without DNA
Peripheral blood cells will be extracted from all blood samples. mRNA will be purified from all samples. The mRNA will be divided to aliquots and will be frozen in -80°C until further processing after all cohort samples have been collected.
mRNAs will be purified from whole blood using the QIAamp RNA purification kit (Quiagen Germany). A DNase I (Qiagen) digestion step is included in order to eliminate genomic DNA.
Serum will be collected from all blood samples. It will will be frozen in -70°C until further processing after all cohort samples have been collected.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01741948
|Clalit health Services|
|Hadassah Medical Organization|
|Principal Investigator:||Ahinoam LevSagie, MD||Clalit Health Services|